康莱特注射液辅助卡瑞利珠单抗联合化疗方案治疗晚期非小细胞肺癌的效果观察

张晓晓; 张祉薇; 董晓倩; 谢曼丽; 邓皖利; 张铭

doi:10.6039/j.issn.1001-0408.2024.15.14

您当前的位置：

首页 >

文章列表页 >

康莱特注射液辅助卡瑞利珠单抗联合化疗方案治疗晚期非小细胞肺癌的效果观察

药物与临床 | 更新时间：2024-08-11

- 康莱特注射液辅助卡瑞利珠单抗联合化疗方案治疗晚期非小细胞肺癌的效果观察
- Effect observation of Kanglaite injection assisted with camrelizumab combined with chemotherapy in the treatment of advanced NSCLC
- 中国药房 2024年35卷第15期页码：1882-1887
- 作者机构：
  
  上海中医药大学附属普陀医院中医肿瘤科，上海　200062
- 作者简介：
  
  副主任医师，硕士生导师，硕士。研究方向：中医药防治恶性肿瘤。E-mail：zxxgoodluck@163.com
- 基金信息：
  
  上海市科技计划项目(20Y21900600);全国（上海市）名中医普陀传承工作室建设项目(ptzygzs2101);上海市普陀区中医临床重点专科建设项目(ptzyzk2101)
- DOI：10.6039/j.issn.1001-0408.2024.15.14
  中图分类号： R969.4;R979.1
- 纸质出版日期：2024-08-15，
  
  收稿日期：2024-01-20，
  
  修回日期：2024-06-15，
- 稿件说明：
扫描看全文
张晓晓,张祉薇,董晓倩等.康莱特注射液辅助卡瑞利珠单抗联合化疗方案治疗晚期非小细胞肺癌的效果观察 ^Δ[J].中国药房,2024,35(15):1882-1887.

ZHANG Xiaoxiao,ZHANG Zhiwei,DONG Xiaoqian,et al.Effect observation of Kanglaite injection assisted with camrelizumab combined with chemotherapy in the treatment of advanced NSCLC[J].ZHONGGUO YAOFANG,2024,35(15):1882-1887.
张晓晓,张祉薇,董晓倩等.康莱特注射液辅助卡瑞利珠单抗联合化疗方案治疗晚期非小细胞肺癌的效果观察 ^Δ[J].中国药房,2024,35(15):1882-1887. DOI： 10.6039/j.issn.1001-0408.2024.15.14.

ZHANG Xiaoxiao,ZHANG Zhiwei,DONG Xiaoqian,et al.Effect observation of Kanglaite injection assisted with camrelizumab combined with chemotherapy in the treatment of advanced NSCLC[J].ZHONGGUO YAOFANG,2024,35(15):1882-1887. DOI： 10.6039/j.issn.1001-0408.2024.15.14.

摘要

目的

观察康莱特注射液辅助卡瑞利珠单抗联合化疗方案治疗晚期非小细胞肺癌（NSCLC）的临床效果。

方法

回顾性选择2018年1月1日至2022年12月1日在我院中医肿瘤科住院治疗的192例晚期NSCLC患者为研究对象，根据患者在卡瑞利珠单抗联合化疗（卡铂+培美曲塞）方案的基础上是否加用康莱特注射液分为观察组（加用，104例）和对照组（不加用，88例）。对比两组患者在治疗2、4、6个周期后的近期治疗效果，治疗前、治疗3个周期后、治疗结束时的外周血免疫功能指标和血清肿瘤标志物水平，以及远期治疗效果和住院治疗期间的不良反应发生情况。

结果

在治疗3个周期后及治疗结束时，观察组患者外周血中CD4

T淋巴细胞比例和CD4

/CD8

均明显高于对照组（

＜0.05），血清中癌胚抗原和细胞角质蛋白19片段抗原21-1水平均明显低于对照组（

＜0.05）；观察组患者的总生存期明显长于对照组（

＜0.05），观察组与对照组患者的中位总生存期分别为（185.27±38.21）、（132.11±34.23） d；两组患者住院治疗期间出现的总体不良反应及≥3级不良反应比较，差异均无统计学意义（

＞0.05）。

结论

在卡瑞利珠单抗联合化疗方案的基础上加用康莱特注射液可进一步提高晚期NSCLC患者的免疫力，延长患者总生存期。

Abstract

OBJECTIVE

To observe the clinical efficacy of Kanglaite injection assisted with camrelizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer （NSCLC）.

METHODS

A total of 192 patients with advanced NSCLC and hospitalized in the TCM oncology department of our hospital from January 1st， 2018 to December 1st， 2022 were retrospectively selected as the study objects， and were divided into observation group （additional use，

＝104） and control group （without additional use，

＝88） according to whether the patients additionally received Kanglaite injection based on camrelizumab combined with chemotherapy （carboplatin+pemetrexed）. The short-term therapeutic effects of 2，4 and 6 cycles were compared between the two groups. The levels of peripheral blood immune function indexes and serum tumor markers were compared before treatment， after 3 cycles of treatment and after treatment. The long-term therapeutic effects as well as the occurrence of adverse drug reaction（ADR） during hospitalization were compared between the two groups.

RESULTS

After 3 treatment cycles and at the end of treatment， the CD4

T lymphocyte ratio and CD4

/CD8

in the observation group were notably greater than the control group （

＜0.05）； the levels of serum carcinoembryonic antigen and cytokeratin 19 fragment antigen 21-1 were significantly lower than those in the control group （

＜0.05）. The overall survival of the observation group was significantly longer than that of the control group （

＜0.05）， and the median overall survival was （185.27±38.21） d and （132.11±34.23） d， respectively. There were no significant differences in the whole ADR and grade ≥3 ADR between the two groups during hospitalization（

＞0.05）.

CONCLUSIONS

Based on camrelizumab combined with chemotherapy， the addition of Kanglaite injection can enhance immunological response and prolong overall survival in advanced NSCLC patients.

关键词

康莱特注射液卡瑞利珠单抗联合化疗方案非小细胞肺癌临床疗效总生存期

Keywords

camrelizumabcombination chemotherapynon-small cell lung cancerclinical efficacyoverall survival

references

吴国明，钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/OL]. 中华肺部疾病杂志（电子版），2019，12（4）：405-408[2023-11-16]. https：//kns.cnki.net/kcms2/article/abstract?v=6RtRr0kVasuDa3rvQ5mhH0eSGeGOAs3D7-JIkdeHOUC4QlPKYhIkkApkU9twrUuBbaR96_oD1r6E-lB0GilVdkeL0ziyCS4GAqAlUyA2YaV5WRUf7Qnpm1-CpfjW5e7iUK0TtO_k1BTQkNDvuwoNpiuwayMMVZ-46idsxJJYSskcJbJH6bXIdqdYCXiaeeXygi9Ceb6NYkpeg-XBOI2nVttUjQ==&uniplatform=NZKPT&language=CHS. DOI：10.3877/cma.j.issn.1674- 6902.2019.04.001https://kns.cnki.net/kcms2/article/abstract?v=6RtRr0kVasuDa3rvQ5mhH0eSGeGOAs3D7-JIkdeHOUC4QlPKYhIkkApkU9twrUuBbaR96_oD1r6E-lB0GilVdkeL0ziyCS4GAqAlUyA2YaV5WRUf7Qnpm1-CpfjW5e7iUK0TtO_k1BTQkNDvuwoNpiuwayMMVZ-46idsxJJYSskcJbJH6bXIdqdYCXiaeeXygi9Ceb6NYkpeg-XBOI2nVttUjQ==&uniplatform=NZKPT&language=CHS.DOI:10.3877/cma.j.issn.1674-6902.2019.04.001.

WU G M，QIAN G S. Research progress and new concept of targeted therapy for non-small cell lung cancer[J/OL]. Chin J Lung Dis Electron Ed，2019，12（4）：405-408[2023-11-16]. https：//kns.cnki.net/kcms2/article/abstract?v=6Rt-Rr0kVasuDa3rvQ5mhH0eSGeGOAs3D7JIkdeHOUC4Ql-PKYhIkkApkU9twrUuBbaR96_oD1r6E-lB0GilVdkeL0ziyCS4GAqAlUyA2YaV5WRUf7Qnpm1CpfjW5e7iUK0Tt-O_k1BTQkNDvuwoNpiuwayMMVZ46idsxJJYSskcJbJH-6bXIdqdYCXiaeeXygi9Ceb6NYkpegXBOI2nVttUjQ==&uniplatform=NZKPT&language=CHS.DOI：10.3877/cma.j.issn.1674-6902.2019.04.001https://kns.cnki.net/kcms2/article/abstract?v=6Rt-Rr0kVasuDa3rvQ5mhH0eSGeGOAs3D7JIkdeHOUC4Ql-PKYhIkkApkU9twrUuBbaR96_oD1r6E-lB0GilVdkeL0ziyCS4GAqAlUyA2YaV5WRUf7Qnpm1CpfjW5e7iUK0Tt-O_k1BTQkNDvuwoNpiuwayMMVZ46idsxJJYSskcJbJH-6bXIdqdYCXiaeeXygi9Ceb6NYkpegXBOI2nVttUjQ==&uniplatform=NZKPT&language=CHS.DOI:10.3877/cma.j.issn.1674-6902.2019.04.001.

UPRETY D，MANDREKAR S J，WIGLE D，et al. Neoadjuvant immunotherapy for NSCLC：current concepts and future approaches[J]. J Thorac Oncol，2020，15（8）：1281-1297.

YI M，ZHENG X L，NIU M K，et al. Combination strategies with PD-1/PD-L1 blockade：current advances and future directions[J]. Mol Cancer，2022，21（1）：28.

梁华，葛明珠，李新，等. 老年局部晚期食管癌卡瑞利珠单抗联合白蛋白紫杉醇序贯放疗的临床观察[J]. 中华肿瘤防治杂志，2022，29（20）：1495-1499.

LIANG H，GE M Z，LI X，et al. Efficacy and safety for camrelizumab combined with albumin-bound paclitaxel and sequential thoracic radiotherapy in elderly locally advanced esophageal cancer[J]. Chin J Cancer Prev Treat，2022，29（20）：1495-1499.

买佳琪，安成，钟华，等. 康莱特注射液联合化疗对晚期非小细胞肺癌患者血清肿瘤标志物的影响[J]. 癌症进展，2023，21（3）：313-316.

MAI J Q，AN C，ZHONG H，et al. Effect of Kanglaite injection combined with chemotherapy on serum tumor marker in patients with advanced non-small cell lung cancer[J]. Oncol Prog，2023，21（3）：313-316.

SCHWARTZ L H，LITIÈRE S，VRIES E D，et al. RECIST 1.1-update and clarification：from the RECIST Committee[J]. Eur J Cancer，2016，62：132-137.

董骏，吴芳芳. mFOLFOX6与FOLFOX4化疗方案治疗直肠癌的临床疗效及安全性分析[J/OL]. 中华消化病与影像杂志（电子版），2023，13（4）：236-240[2023-11-16]. https：//kns.cnki.net/kcms2/article/abstract?v=6RtRr0kVasu-https://kns.cnki.net/kcms2/article/abstract?v=6RtRr0kVasu-

0qEVZCGDj6S6ZUtIb5ChJrAV89nRfS20cyIn7EDvq2UF4-DpBvWx3cT033vf1KXt6pjpUli3FngKjjptFHLMqNVz4_5cjX7YJwNIQApYYhw0XUs0L1K541b_Lakjt8SXQpif- gcJ1aPEgmVPH2pXKEINzVMU_aWgGMjUPNGR1C- wrwKsR0r6D32g0R-sOMO1PYs8yH0HhcHGg==&uniplatform=NZKPT&language=CHS.DOI：10.3877/cma.j.issn.2095-2015.2023.04.010. DONG Jhttp://dx.doi.org/10.3877/cma.j.issn.2095-2015.2023.04.010.DONGJ，WUF F. Clinical efficacy and safety analysis of mFOLFOX6 and FOLFOX4 chemotherapy regimens in the treatment of rectal cancer[J/OL]. Chin J Dig Med Imageology Electron Ed，2023，13（4）：236-240[2023-11-16]. https：//kns.cnki.net/kcms2/article/abstract?v=6RtRr0kVasu-https://kns.cnki.net/kcms2/article/abstract?v=6RtRr0kVasu-

CASCONE T，FRADETTE J，PRADHAN M，et al. Tumor immunology and immunotherapy of non-small-cell lung cancer[J]. Cold Spring Harb Perspect Med，2022，12（5）：a037895.

LI B，CHAN H L，CHEN P P. Immune checkpoint inhibitors：basics and challenges[J]. Curr Med Chem，2019，26（17）：3009-3025.

REN S X，CHEN J H，XU X X，et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC（CameL-sq）：a phase 3 trial[J]. J Thorac Oncol，2022，17（4）：544-557.

田洁，付文华，张媛，等. 卡瑞利珠单抗联合传统化疗在晚期非鳞非小细胞肺癌中的临床疗效[J]. 湖南师范大学学报（医学版），2021，18（5）：214-216.

TIAN J，FU W H，ZHANG Y，et al. The clinical efficacy of camrelizumab plus carboplatin and pemetrexed in the treatment of advanced non-squamous non-small cell lung cancer[J]. J Hunan Norm Univ Med Sci，2021，18（5）：214-216.

ZHOU C C，CHEN G Y，HUANG Y C，et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer （CameL）：a randomised，open-label，multicentre，phase 3 trial[J]. Lancet Respir Med，2021，9（3）：305-314.

王璐瑶，罗钺，黄蓉，等. 肺癌虚证证候的研究现状及展望[J]. 中华中医药杂志，2023，38（10）：4548-4552.

WANG L Y，LUO Y，HUANG R，et al. Research status quo and prospect of lung cancer in deficiency syndrome[J]. China J Tradit Chin Med Pharm，2023，38（10）：4548-4552.

周娟，付萍，韩慧，等. 康莱特注射液联合化疗对非小细胞肺癌中晚期患者肺功能及癌痛的影响[J]. 湖北中医药大学学报，2021，23（4）：34-36.

ZHOU J，FU P，HAN H，et al. Effect of Kanglaite injection adjuvant chemotherapy on lung function and cancer pain in patients with advanced non-small cell lung carcinoma[J]. J Hubei Univ Chin Med，2021，23（4）：34-36.

LU T C，YU J W，GAO R K，et al. Chinese patent medicine Kanglaite injection for non-small-cell lung cancer：an overview of systematic reviews[J]. J Ethnopharmacol，2023，302（Pt A）：115814.

HUANG X M，WANG J，LIN W J，et al. Kanglaite injection plus platinum-based chemotherapy for stage Ⅲ/Ⅳ non-small cell lung cancer：a meta-analysis of 27 RCTs[J]. Phytomedicine，2020，67：153154.

李娟，吴喆，李杰. 基于循证医学的康莱特注射液治疗非小细胞肺癌作用特点及分子机制研究[J]. 吉林中医药，2020，40（12）：1675-1678.

LI J，WU Z，LI J. Study on the role and molecular mechanism of Kanglaite injection in the treatment of non-small cell lung cancer based on evidence-based medicine[J]. Jilin J Chin Med，2020，40（12）：1675-1678.

WEN J X，YANG T，WANG J，et al. Kanglaite injection combined with chemotherapy versus chemotherapy alone for the improvement of clinical efficacy and immune function in patients with advanced non-small-cell lung cancer：a systematic review and meta-analysis[J]. Evid Based Complement Alternat Med，2020，2020：8586596.

桂雪梅，代丽，袁钦伟，等. 康莱特注射液在化疗药物治疗晚期非小细胞肺癌中的作用及对CD3+、CD4+、NK、CD4+/CD8+水平的影响[J]. 中华中医药学刊，2020，38（5）：147-150.

GUI X M，DAI L，YUAN Q W，et al. Effects of Kanglaite injection on levels of CD3+，CD4+，NK and CD4+/CD8+ in patients with advanced non-small cell lung cancer[J]. Chin Arch Tradit Chin Med，2020，38（5）：147-150.

高亚军，柏大鹏，李婵. 康莱特注射液联合紫杉醇+顺铂化疗治疗晚期非小细胞肺癌的疗效及对患者免疫功能的影响[J]. 癌症进展，2022，20（4）：403-406.

GAO Y J，BAI D P，LI C. Efficacy of Kanglaite injection combined with paclitaxel+cisplatin chemotherapy in the treatment of advanced non-small cell lung cancer and its effect on the immune function of patients[J]. Oncol Prog，2022，20（4）：403-406.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

西妥昔单抗联合化疗药物对比单用化疗药物治疗转移性结直肠癌疗效的Meta分析